New Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntington's Disease
Go back to New Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntington's Disease| (NASDAQ: AKCA) | Delayed: 18.17 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.17 | 52 Week High | $ | |||
| Open | $22.77 | 52 Week Low | $ | |||
| Day High | $18.17 | P/E | N/A | |||
| Day Low | $18.17 | EPS | $ | |||
| Volume | 2,023 | |||||
| (NASDAQ: IONS) | Delayed: 55.42 -1.52 (2.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $56.94 | 52 Week High | $62.68 | |||
| Open | $56.79 | 52 Week Low | $19.59 | |||
| Day High | $57.16 | P/E | N/A | |||
| Day Low | $55.37 | EPS | $0.00 | |||
| Volume | 2,406,994 | |||||
